Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. Additionally we are shipping Lipoprotein Lipase Kits (48) and Lipoprotein Lipase Proteins (18) and many more products for this protein.
Showing 10 out of 137 products:
Human Monoclonal Lipoprotein Lipase Primary Antibody for FACS, ELISA - ABIN1042621
Peterson, Ayyobi, Ma, Henderson, Reina, Deeb, Santamarina-Fojo, Hayden, Brunzell: Structural and functional consequences of missense mutations in exon 5 of the lipoprotein lipase gene. in Journal of lipid research 2002
Show all 4 references for ABIN1042621
Human Monoclonal Lipoprotein Lipase Primary Antibody for ELISA, WB - ABIN969262
Berk, Johnson, Lee, Zhang, Boozer, Pi-Sunyer, Fried, Albu: Higher post-absorptive skeletal muscle LPL activity in African American vs. non-Hispanic White pre-menopausal women. in Obesity (Silver Spring, Md.) 2008
Show all 2 references for ABIN969262
Cow (Bovine) Monoclonal Lipoprotein Lipase Primary Antibody for EIA, Func - ABIN125994
Voyta, Via, Kinnunen, Sparrow, Gotto, Smith: Monoclonal antibodies against bovine milk lipoprotein lipase. Characterization of an antibody specific for the apolipoprotein C-II binding site. in The Journal of biological chemistry 1985
lipoprotein lipase polymorphism was not associated with the incidence of coronary heart disease in Sudan.
Individuals carrying the lipoprotein lipase (LPL) rs12678919 polymorphism (A --> G) had no significant change in the risk of developing AMD (show AMD1 Antibodies).
Asn291Ser(rs268), HindIII(rs320) and Ser447Ter(rs328) polymorphisms of lipoprotein lipase were associated with a risk of Alzheimer disease.[meta-analysis]
in well characterized FCHL (show USF1 Antibodies) individuals, variants in LDLR (show LDLR Antibodies) and LPL (show LCP1 Antibodies) provide a small contribution to dyslipidemia
polymorphisms in LPL (show LCP1 Antibodies) protect HIV-infected patients from developing atherogenic dyslipidemia in a dose-dependent manner
role of lipoprotein lipase in atherosclerosis
our results show the involvement of the variants of ESR1 (show ESR1 Antibodies), LPL (show LCP1 Antibodies) and CETP (show CETP Antibodies) genes in metabolic events related to MetS (show ETV3 Antibodies) or some of its features.
It can be suggested that the pronounced hypolipidemic effect of rosuvastatin in homozygotes +495GG of the LPL (show LCP1 Antibodies) gene is associated with modulation of the LPL (show LCP1 Antibodies) activity, as it has been previously reported for other statin drugs.
Both common and uncommon/rare LPL (show LCP1 Antibodies) variants/haplotypes may affect plasma lipoprotein-lipid levels in general African population.
the LPL (show LCP1 Antibodies) gene polymorphism was determined to be the main factor related to insulin (show INS Antibodies) resistance in women with gestational diabetes.
apoC-I (show APOC1 Antibodies) and apoC-III (show APOC3 Antibodies) inhibit lipolysis by displacing LPL from lipid emulsion particles. We also propose a role for these apolipoproteins in the irreversible inactivation of LPL by factors such as angptl4 (show ANGPTL4 Antibodies).
ANGPTL4 (show ANGPTL4 Antibodies) is more accurately described as a reversible, noncompetitive inhibitor of LPL.
Our findings confirmed that three novel SNPs we identified in the LPL gene can affect fatty acid composition and carcass traits. Therefore, selection for AA and GA genotypes should be recommended to genetically improve beef quality and flavor.
Single nucleotide polymorphisms of the LPL gene might be useful genetic markers for growth traits in the bovine reproduction and breeding.
Results describe the functional role of the secondary structure in the lipoprotein lipase-binding portion of apolipoprotein CII (show APOC2 Antibodies).
regions that are responsive to activation by apoC-II (show APOC2 Antibodies)
domain (192-238) is absolutely necessary for apolipoprotein AV (show APOA5 Antibodies) in lipid binding and lipoprotein lipase activation
feeding induces lipasin, activating the lipasin-Angptl3 (show ANGPTL3 Antibodies) pathway, which inhibits LPL in cardiac and skeletal muscles to direct circulating TAG to WAT for storage
MiR (show MLXIP Antibodies)-590 agomir down-regulates LPL mRNA and protein expression in a mouse model of atherosclerosis.
Deficiency of Lipoprotein Lipase in Neurons Decreases AMPA (show GRIA3 Antibodies) Receptor Phosphorylation and Leads to Neurobehavioral Abnormalities in Mice
Systemic LPL deletion results in impaired glucose tolerance, whole-body and tissue-specific insulin (show INS Antibodies) resistance, which is associated with tissue lipid deposition in various insulin (show INS Antibodies) target tissues
Results indicated that aggregation of alpha-syn and reduction of UCHL1 (show UCHL1 Antibodies) expression in LPL-deficient mice may affect synaptic function.
the amount of LPL expressed in muscle and heart governed both the binding of chylomicron particles and the assimilation of chylomicron lipids in the tissue.
Maternal overnutrition induces LPL expression in trophoblasts by reducing the inhibitory effect of SIRT1 (show SIRT1 Antibodies) on PPARgamma (show PPARG Antibodies).
Lipoprotein lipase is an important modulator of lipid uptake and storage in hypothalamic neurons.
Results suggest that impaired synaptic vesicle recycling results from deficient docosahexaenoic acid and arachidonic acid and contributes to the presynaptic dysfunction and plasticity impairment in LPL-deficient neurons
Adipocyte-specific Sel1L (show SEL1L Antibodies)-deficient (AKO) mice are resistant to diet-induced obesity. Sel1L (show SEL1L Antibodies) stabilizes and prevents LPL dimers from aggregation in the endoplasmic reticulum.
LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism.
, O 1-4-5
, adipose lipoprotein lipase
, triacylglycerol lipase